Valneva Announces the Modification of the Conditions of Participation in its Extraordinary General Meeting of December 22, 20...
07 Dicembre 2020 - 03:00PM
Valneva Announces the Modification of the Conditions of
Participation in its Extraordinary General Meeting of December 22,
2020, which will be held as a closed meeting
Saint-Herblain (France), December 7, 2020 –
Valneva SE (“Valneva” or “the Company”) announces that due to the
current COVID-19 epidemic and in accordance with the French
Ordinance No. 2020-321 dated March 25, 2020 (as amended and
extended by the French Ordinance No. 2020-1497 dated December 2,
2020), the Company has decided to modify the conditions of
participation in its Extraordinary General Meeting of
December 22, 2020, 2:00 p.m. CET. This General Meeting
will therefore be held at Valneva's registered office without the
physical presence of its shareholders and other persons normally
authorized to attend.
Valneva will provide a live webcast of the
conference so as to allow all persons normally authorized to attend
the General Meeting to follow it remotely. This webcast will be
accessible on the homepage or in the “Investors” / “Videos and
Webcasts” section of the Company’s website, www.valneva.com, and a
replay will be available after the event.
The special conditions of participation in this
closed General Meeting are published in the Bulletin des Annonces
Légales Obligatoires of December 7, 2020. They are also available
in the “Investors” / “Extraordinary General Meeting 2020” section
of the Company’s website, www.valneva.com.
Valneva SE’s shareholders are invited to vote in
advance of the Extraordinary General Meeting, either by mail
(recommended method) or by giving a proxy, using the form provided
to them for this purpose among the General Meeting documents made
available on the Company’s website.No admission cards will be sent
to the shareholders.
Please note that during the General Meeting, it
will not be possible to ask questions, submit draft amendments or
submit new resolutions.
Shareholders can obtain the General Meeting
documents referred to in Articles R. 225-81 and R. 225-83 of the
French Commercial Code upon request to the Company. Valneva
recommends that shareholders send their requests via email to the
following address: assemblee.generale@valneva.com.
In addition, shareholders may request that the
Company send them the documents and information referred to in
Articles L. 225-115, L. 225-116 and L. 225-117 of the French
Commercial Code (including the list of shareholders) that would not
otherwise be available on the Company’s website. These requests
must be made in the time frames provided in Articles R. 225-89, R.
225-90 and L. 225-117 of the French Commercial Code. Valneva
recommends that its shareholders send these requests to the
aforementioned email address.
Generally, considering the possible slowdown of
postal services in the context of COVID-19, Valneva encourages its
shareholders to send all requests or correspondence related to the
General Meeting via email to the following address:
assemblee.generale@valneva.com.
The Company finally recommends that its
shareholders regularly consult the section related to the General
Meeting on the Company’s website: www.valneva.com (Section
“Investors” / “Extraordinary General Meeting 2020”).
Contact
details General Meeting departmentValneva SEService
Assemblée Générale6 rue Alain Bombard, 44800 Saint-Herblain
(France)assemblee.generale@valneva.com |
|
About Valneva SEValneva is a
specialty vaccine company focused on prevention against diseases
with major unmet needs. The Company has several vaccines in
development including unique vaccines against Lyme disease,
COVID-19 and chikungunya. Valneva’s portfolio includes two
commercial vaccines for travelers: IXIARO®/JESPECT® indicated for
the prevention of Japanese encephalitis and DUKORAL® indicated for
the prevention of cholera and, in some countries, prevention of
diarrhea caused by ETEC.
Valneva
Investor and Media ContactsLaetitia
Bachelot-FontaineDirector Investor Relations & Corporate
CommunicationsM +33 (0)6 4516
7099investors@valneva.com |
Teresa
PinzolitsCorporate Communications SpecialistT +43 (0)1 20620
1116communications@valneva.com |
Forward-Looking Statements
This press release contains certain
forward-looking statements relating to the business of Valneva,
including with respect to the potential Offering, the progress,
timing and completion of research, development and clinical trials
for product candidates, the ability to manufacture, market,
commercialize and achieve market acceptance for product candidates,
the ability to protect intellectual property and operate the
business without infringing on the intellectual property rights of
others, estimates for future performance and estimates regarding
anticipated operating losses, future revenues, capital requirements
and needs for additional financing. In addition, even if the actual
results or development of Valneva are consistent with the
forward-looking statements contained in this press release, those
results or developments of Valneva may not be indicative of their
in the future. In some cases, you can identify forward-looking
statements by words such as "could," "should," "may," "expects,"
"anticipates," "believes," "intends," "estimates," "aims,"
"targets," or similar words. These forward-looking statements are
based largely on the current expectations of Valneva as of the date
of this press release and are subject to a number of known and
unknown risks and uncertainties and other factors that may cause
actual results, performance or achievements to be materially
different from any future results, performance or achievement
expressed or implied by these forward-looking statements. In
particular, the expectations of Valneva could be affected by, among
other things, uncertainties involved in the development and
manufacture of vaccines, unexpected clinical trial results,
unexpected regulatory actions or delays, competition in general,
currency fluctuations, the impact of the global and European credit
crisis, and the ability to obtain or maintain patent or other
proprietary intellectual property protection. In light of these
risks and uncertainties, there can be no assurance that the
forward-looking statements made in this press release will in fact
be realized. Valneva is providing the information in these
materials as of this press release, and disclaim any intention or
obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events,
or otherwise.
Please refer to the Universal Registration
Document filed with the Autorité des Marchés Financiers on March
30, 2020 under n° D.20-0217 for additional information in relation
to such factors, risks and uncertainties.
- 2020_12_07_ VLA_EGM_PR_EN_Final
Grafico Azioni Valneva (EU:VLA)
Storico
Da Feb 2024 a Mar 2024
Grafico Azioni Valneva (EU:VLA)
Storico
Da Mar 2023 a Mar 2024